Albert David (ALBERTDAVD) Share Price Rises 15.77% Today as Micro Cap Stock Jumps to Rs 838

Published: 07 August 2026 at 11:30:18 AM IST

Albert David traded at Rs 838, up 15.77% today, with a market capitalisation of Rs 413.11 crore.

Albert David Share Price was at Rs 838 in today’s session, up 15.77% from the previous close of Rs 723.85, taking the company’s market capitalisation to Rs 413.11 crore. In Stock Market Today trade, the pharmaceutical counter stood out among market movers after a sharp single-day price rise in the micro cap segment.

For investors tracking Albert David Share Price Today, the verified data confirms a strong move in price, but it does not establish a company-specific catalyst behind the rise. That matters because Albert David Stock News is currently being driven by the market action itself rather than any stated trigger in the supplied dataset. The stock opened at Rs 860, also its day’s high, before slipping to an intraday low of Rs 787 and then trading at Rs 838 at the time captured here.

From a financial context standpoint, Albert David is valued at a P/E ratio of 18.31 and a P/B ratio of 1.06, while return metrics show ROE of 13.46% and ROCE of 18.1%. In the same Pharmaceuticals & Drugs industry, those numbers place the company in an interesting valuation and profitability position relative to peers and benchmark medians. Univest notes that the stock is trending because of its outsized day move, while investors should monitor whether the price action is sustained and how its valuation compares with the sector backdrop.

Albert David (ALBERTDAVD) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 838
Previous Close	Rs 723.85
Today's Move	+Rs 114.15 (+15.77%)
Open	Rs 860
High	Rs 860
Low	Rs 787
Turnover	Rs 1.01 crore
Market Capitalisation	Rs 413.11 crore
Market Cap Category	Micro Cap

Albert David (ALBERTDAVD) traded at Rs 838. versus the previous close of Rs 723.85, a rise of 15.77%. The stock opened at Rs 860, reached Rs 860, touched Rs 787.

Albert David (ALBERTDAVD) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 413.11 crore
P/E Ratio	18.31x
P/B Ratio	1.06x
ROE	13.46%
ROCE	18.1%
EPS	Rs 39.54
Dividend Yield	0.69%

Albert David (ALBERTDAVD) fundamental metrics show P/E 18.31x, P/B 1.06x, ROE 13.46%, ROCE 18.1%. These figures provide context only and are not a buy or sell signal.

Albert David Fundamental Analysis shows a micro cap pharmaceutical company with moderate valuation multiples and profitability metrics that compare reasonably with its industry benchmark. The stock’s sharp move today brings attention not just to price action, but also to whether the underlying numbers justify continued investor tracking.

Albert David has a market capitalisation of Rs 413.11 crore, which places it below the industry average market cap of Rs 500.48 crore but above the same-industry median of Rs 144.63 crore across 137 companies. Its P/E ratio of 18.31 sits below the industry median of 25.99 and far below the industry average of 81.5, within a broad observed range of 3.3 to 3493.04. On a price-to-book basis, the company’s P/B ratio is 1.06, which is below the benchmark median of 1.86 and the benchmark average of 2.51.

Profitability also offers useful context for Albert David Stock Analysis. ROE stands at 13.46%, ahead of the industry median of 10.59% and well above the average of 8.23%. ROCE is 18.1%, again stronger than the median of 12.98% and the average of 15.71%. These numbers suggest the company’s return profile is not weak relative to the broader Pharmaceuticals & Drugs set used here.

EPS comes in at 39.54, which shows the earnings attributable to each share based on the supplied data. Dividend yield is 0.69, a reminder that the stock also carries a historical payout component, though yield data should be read as current or trailing information rather than any promise of future distributions.

For readers searching Albert David Financial Results or Albert David Earnings context, today’s data does not add revenue, net profit, margin, leverage or cash-flow figures. Even so, the available valuation and return ratios show that Albert David Share Price is not rising from an obviously stretched base on the metrics supplied. That makes the peer and sector comparison especially relevant.

Albert David has a market capitalisation of Rs 413.11 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 18.31x, P/B at 1.06x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 13.46% and ROCE of 18.1%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 39.54, dividend yield of 0.69%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 25.99x, median ROE of 10.59%, median ROCE of 12.98%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	18.31x
Benchmark Median P/E	25.99x
Benchmark Average P/E	81.5x
Benchmark P/E Range	3.3x to 3,493.04x
Company P/B Ratio	1.06x
Benchmark Median P/B	1.86x
Company ROE	13.46%
Benchmark Median ROE	10.59%
Company ROCE	18.1%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 413.11 crore
Benchmark Median Market Cap	Rs 144.63 crore

Albert David (ALBERTDAVD) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Albert David (ALBERTDAVD) has a P/E ratio of 18.31x, which is below the benchmark median of 25.99x, a difference of -29.55%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Albert David (ALBERTDAVD) has a ROE of 13.46%, which is above the benchmark median of 10.59%, a difference of +27.1%. Albert David (ALBERTDAVD) has a ROCE of 18.1%, which is above the benchmark median of 12.98%, a difference of +39.45%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Albert David operates in Healthcare, specifically the Pharmaceuticals & Drugs industry. Against that backdrop, the stock’s valuation appears lower than the industry benchmark on both P/E and P/B, while its ROE and ROCE are higher than the benchmark medians and averages supplied for the same industry set.

The sector snapshot used here covers the same industry and includes 137 companies for market capitalisation comparison, 104 companies for P/E, and 136 companies each for P/B, ROE and ROCE. That scope matters because it gives Albert David Share Price a more grounded comparison than a generic healthcare label alone.

On valuation, the company’s P/E of 18.31 is below the benchmark median of 25.99 and far below the average of 81.5. The industry range is wide, from 3.3 to 3493.04, so the average is influenced by extreme readings. The company’s P/B of 1.06 is also below the benchmark median of 1.86 and average of 2.51, within an industry range of -16.76 to 16.42.

On profitability, Albert David looks firmer. Its ROE of 13.46% exceeds the industry median of 10.59% and average of 8.23%. ROCE of 18.1% is also above the median of 12.98% and average of 15.71%. In market capitalisation terms, Albert David’s Rs 413.11 crore compares with an industry median of Rs 144.63 crore, average of Rs 500.48 crore, minimum of Rs 6.16 crore and maximum of Rs 3,060.41 crore.

For Albert David Market Cap and sector-analysis searches, that mix suggests a company that is smaller than leading listed peers but not at the bottom of the industry pack. Univest sees this as a useful context point: today’s price rise is happening in a stock whose valuation is below sector medians, while return ratios are above them.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis	DCAL	3,060.41	31.3	0.46	-2.89	-0.26
Hikal	HIKAL	2,862.43	0	2.29	15.22	16.15
Kwality Pharmaceuticals	KPL	2,652.52	40.87	8.32	28.21	26.35
Beta Drugs	BETA	2,623.92	67.31	10.65	18.65	22.17
Panacea Biotec	PANACEABIO	2,571.92	0	3.06	0	5.36

Albert David (ALBERTDAVD) has a P/E ratio of 18.31x compared with the displayed peer median of 31.3x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 13.46% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 18.1% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Albert David (ALBERTDAVD) has a market capitalisation of Rs 413.11 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Albert David compares against a supplied peer set in the same Pharmaceuticals & Drugs industry with a smaller market capitalisation but a valuation profile that is often lower than peers. Its return ratios are competitive against some names, though not the strongest across the pack.

Albert David, at Rs 413.11 crore market cap, is much smaller than the supplied peers, which range from Rs 2,072.78 crore for Hester Biosciences to Rs 3,060.41 crore for Dishman Carbogen Amcis That size gap alone can affect how the market reads today’s move, especially in a micro cap counter.

On valuation, Albert David’s P/E of 18.31 is below Dishman Carbogen Amcis at 31.3, Kwality Pharmaceuticals at 40.87, Beta Drugs at 67.31, Sai Parenteral’s at 167.74, Fredun Pharmaceuticals at 46.11 and NGL Fine-Chem at 44.1. It is, however, above Hester Biosciences at 15.31 among the peers where P/E is supplied. Its P/B of 1.06 is lower than Hikal at 2.29, Kwality at 8.32, Beta Drugs at 10.65, Panacea Biotec at 3.06, Solara at 1.93, Sai Parenteral’s at 3.1, Fredun at 6.89, NGL Fine-Chem at 6.45 and Hester at 4.58, though above Dishman’s 0.46.

Profitability is mixed but respectable. Albert David’s ROE of 13.46% is above Dishman’s -2.89%, Panacea Biotec’s 0% and Fredun’s 11.42%, but below Hikal’s 15.22%, Kwality’s 28.21%, Beta Drugs’ 18.65%, Solara’s 17.23%, Sai Parenteral’s 13.9%, NGL Fine-Chem’s 27.9% and Hester’s 16.17%. ROCE at 18.1% is ahead of Dishman’s -0.26%, Hikal’s 16.15%, Panacea’s 5.36%, Solara’s 15.34%, Sai Parenteral’s 12.97%, Fredun’s 13.15% and Hester’s 14.12%, though below Kwality’s 26.35%, Beta’s 22.17% and NGL Fine-Chem’s 33.91%. Univest therefore reads Albert David Share Price as a stock with comparatively lower valuation but mid-range return metrics within its peer basket.

Why Investors Are Watching Albert David

Albert David Stock News is drawing attention because the stock has posted a sharp one-day gain in the micro cap healthcare space while still trading on valuation multiples below several industry and peer benchmarks. That combination naturally puts the counter on shortlists for market watchers looking at price action alongside fundamentals.

• Price move: the stock rose Rs 114.15, or 15.77%, from Rs 723.85 to Rs 838.
• Intraday structure: it opened at Rs 860, touched a low of Rs 787 and remained well above the previous close.
• Valuation context: P/E is 18.31 and P/B is 1.06, both below industry medians.
• Profitability context: ROE is 13.46% and ROCE is 18.1%, both above industry medians.
• Industry position: the company operates in Healthcare, within Pharmaceuticals & Drugs, where benchmark comparison is available across 137 companies.

What investors may monitor next is whether Albert David Share Price Today can hold a meaningful part of this gain and whether the market continues to reward its lower-multiple profile relative to peers. Univest also highlights that, in the absence of a verified company-specific trigger in the supplied data, follow-through in price and any fresh company updates become especially important for Albert David News Today tracking.

About Albert David

Albert David is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. Based on the supplied classification, the company sits within a listed industry group that includes 137 comparable companies for market-cap benchmarking, ranging from small niche names to businesses worth over Rs 3,000 crore.

That industry backdrop is useful because Albert David Share Price often gets interpreted not only as a standalone stock move but also through the lens of pharmaceutical valuations, capital efficiency and relative size. In this case, the company’s market capitalisation of Rs 413.11 crore puts it above the same-industry median of Rs 144.63 crore, though still below the average of Rs 500.48 crore and well below the largest supplied peer at Rs 3,060.41 crore.

The broader peer list attached to the stock places Albert David alongside companies such as Dishman Carbogen Amcis, Hikal, Kwality Pharmaceuticals, Beta Drugs, Panacea Biotec, Solara Active Pharma Sciences, Sai Parenteral’s, Fredun Pharmaceuticals, NGL Fine-Chem and Hester Biosciences. For Albert David Company News and Albert David Latest News searches, that means the stock is best understood as a smaller listed pharmaceuticals player being judged by investors on price, valuation and return ratios rather than sheer scale. Univest uses that industry framing to help readers compare the stock on a like-for-like basis.

Track Albert David Share Price on Univest

Use Albert David (ALBERTDAVD) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors following Albert David Share Price can use Univest to track live market moves, valuation ratios and broader stock context in one place. Albert David Share Price Live tracking is most useful when a stock enters the Top Gainers Today list, because intraday positioning can change quickly even after a strong start.

On Univest, readers can follow Albert David Share Price Today alongside metrics such as P/E ratio, P/B ratio, ROE, ROCE, EPS, dividend yield, market capitalisation and 52-week levels when available. The platform also helps users compare sector benchmarks, review peer positioning and monitor Albert David Share News as fresh market data appears. For investors focused on Albert David NSE and Albert David BSE visibility, a structured dashboard can make day-to-day stock analysis easier without turning market updates into recommendations.

Frequently Asked Questions

Why is Albert David Share Price rising today?

Ans. Albert David Share Price rose because the stock gained 15.77% in the session, moving from Rs 723.85 to Rs 838. The supplied data confirms the price event, but it does not establish a company-specific catalyst for today’s move.

What is Albert David Share Price Today?

Ans. Albert David Share Price Today was Rs 838 at the captured time. The stock was up Rs 114.15 from the previous close of Rs 723.85, after opening at Rs 860 and trading between Rs 787 and Rs 860.

Is Albert David a top gainer today?

Ans. Albert David appeared in a top-gainer style event screen because the stock recorded a sharp same-day gain of 15.77%. In the micro cap segment, that price rise was large enough to make the move market-relevant today.

What does today’s price action show for Albert David?

Ans. Today’s price action shows a gap-up start, with Albert David opening at Rs 860, which was also the day’s high. The stock later touched Rs 787 and traded at Rs 838, still well above the previous close.

What is Albert David’s market capitalisation?

Ans. Albert David’s market capitalisation is Rs 413.11 crore based on the supplied data. That places it in the Micro Cap category and above the same-industry median market cap of Rs 144.63 crore, though below the average of Rs 500.48 crore.

Is Albert David expensive based on valuation ratios?

Ans. Albert David does not look expensive relative to the supplied industry benchmark. Its P/E ratio is 18.31 versus the industry median of 25.99, while its P/B ratio of 1.06 is below the benchmark median of 1.86.

How profitable is Albert David compared with its industry?

Ans. Albert David shows ROE of 13.46% and ROCE of 18.1%. Both are above the same-industry medians of 10.59% and 12.98%, suggesting the company’s return profile is stronger than the benchmark midpoint on supplied figures.

What does EPS and dividend yield indicate for Albert David?

Ans. Albert David’s EPS is 39.54, representing earnings attributable to each share on the supplied data. Its dividend yield is 0.69, indicating a historical payout component relative to the current stock price, not a forward guarantee.

How does Albert David compare with listed peers?

Ans. Albert David is smaller than all supplied peers by market capitalisation, at Rs 413.11 crore. However, its P/E of 18.31 is below many peers, while ROE of 13.46% and ROCE of 18.1% sit in a competitive mid-range.

What should investors monitor next in Albert David Stock News?

Ans. Investors may watch whether Albert David holds today’s gain after rising 15.77%, and whether fresh company updates emerge. Valuation at P/E 18.31 and profitability at ROE 13.46% and ROCE 18.1% also remain important tracking points.